About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01379560

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related...

Lead sponsor: Sucampo Pharma Americas, LLC•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Sucampo Pharma Americas, LLC

Collaborators

Sucampo Pharmaceuticals, Inc.

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥ 50 years at screening
•Ametropy ≤ 3 diopters
•Clear ocular media
•Visual acuity in the study eye \> 20/40

Exclusion Criteria

•Presence of any ocular condition in the study eye (other than AMD) that may progress during the course of the study and could affect central vision, or other ocular conditions that may be a confounding factor in this study
•Blood donation during the previous 3 weeks
•Current smoker or a history of smoking within 5 years of enrollment
•Treatment with protocol-specified prohibited concomitant medications
•Prior exposure to Rescula (unoprostone isopropyl) and or a known sensitivity to any of the components of the study medication (e.g. benzalkonium chloride)

Related studies

RECRUITINGPhase 2

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

NCT06557460 · Dry Age-related Macular Degeneration, Geographic Atrophy

RECRUITINGPhase 1/2

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT07158775 · Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

RECRUITINGPhase 1/2

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

NCT04627428 · Dry Age-related Macular Degeneration

RECRUITINGPhase 3

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

NCT06165068 · Dry Age-related Macular Degeneration

Active Not Recruiting

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896 · Dry Age-related Macular Degeneration, Geographic Atrophy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 10, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment33

Start dateMay 2011

Last updatedDec 10, 2019

Condition

Dry Age-related Macular Degeneration

Locations shown

Medical University of Vienna

Vienna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 10, 2019Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions